|17th December 2020||David S. Grayzel||1,700,000||Open or private sale||$18.10||$30,770,000.00|
|17th December 2020||Venture Fund Ix, L.P. Atlas||1,700,000||Open or private sale||$18.10||$30,770,000.00|
|25th November 2020||Jessica Fees||227||Exercise of derivative||$4.14||$938.87|
|25th November 2020||Jessica Fees||173||Exercise of derivative||$4.27||$738.71|
|25th November 2020||Jessica Fees||982||Exercise of derivative||$5.41||$5,314.58|
|25th November 2020||Jessica Fees||1||Exercise of derivative||$4.27||$4.27|
|28th October 2020||Jessica Fees||122||Exercise of derivative||$4.27||$520.94|
|28th October 2020||Jessica Fees||4,773||Exercise of derivative||$4.14||$19,741.13|
|14th October 2020||Robert W. Ross||4,000||Open or private sale||$10.05||$40,200.00|
|14th September 2020||Enterprise Associates 14, L.P. New||2,000,000||Other acquisition or disposition||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The company focuses on biological pathways critical to the immunosuppressive tumor microenvironment.